|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 05, 2016 ) The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.
Publisher's Metastatic Pancreatic Cancer Healthcare Industry report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inquire before Purchasing Report @ http://www.reportsweb.com/inquiry&RW0001231629/buying
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001231629/sample
Table of Content: An Overview
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Pancreatic Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Pancreatic Cancer - Overview 11
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Pancreatic Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Metastatic Pancreatic Cancer - Products under Development by Companies 21
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 26
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 27
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001231629/discount
AbbVie Inc. 27
Aduro BioTech, Inc. 28
ArQule, Inc. 29
Array BioPharma Inc. 30
AstraZeneca Plc 31
Axcentua Pharmaceuticals AB 32
Berg LLC 33
Bionomics Limited 34
Boehringer Ingelheim GmbH 35
Boston Biomedical, Inc. 36
Bristol-Myers Squibb Company 37
Celgene Corporation 38
Clovis Oncology, Inc. 39
Cornerstone Pharmaceuticals, Inc. 40
CTI BioPharma Corp. 41
CytRx Corporation 42
Eleison Pharmaceuticals LLC 43
Eli Lilly and Company 44
Ensol Biosciences Inc. 45
Erytech Pharma SA 46
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001231629/buy/2000
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
